Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1660
-0.0042 (-2.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cns Pharmaceuticals Inc
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial
December 28, 2022
Via
Investor Brand Network
Machine Learning Effort Enables Large-Scale Cancer Study to Improve Boundary Detection
December 27, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations
December 22, 2022
Via
Investor Brand Network
New Study Finds Localized Cooling of Brain Tumors Slows Growth in Mice Models
December 19, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward
December 14, 2022
Via
Investor Brand Network
Four Facts You Need to Know About Brain Cancer
November 29, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment
December 14, 2022
Via
Investor Brand Network
Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors
December 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
December 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial
December 08, 2022
Via
Investor Brand Network
Research Recommends Reduction of Pediatric Brain Irradiation During Cancer Treatment
December 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event
December 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering
December 01, 2022
Via
Investor Brand Network
Why Shares Of Chinese Companies Are Trading Higher? Here Are 45 Stocks Moving In Tuesday's Mid-Day Session
November 29, 2022
Gainers Otonomy, Inc. (NASDAQ: OTIC) shares surged 74.2% to $0.1866. Otonomy recently posted a Q3 loss of $0.18 per share.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
On Friday, 72 companies hit new 52-week lows.
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place
November 29, 2022
Via
Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
November 29, 2022
Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday!
Via
InvestorPlace
Why Elbit Systems Shares Are Trading Lower By Over 10%; Here Are 24 Stocks Moving Premarket
November 29, 2022
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares rose 26.3% to $0.7994 in pre-market trading after the company received FDA 510K premarket clearance for PainShield Plus, its dual-actuator ultrasound...
Via
Benzinga
European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment
November 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
November 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial
November 22, 2022
Via
Investor Brand Network
Implanted Pump Holds Promise in Treating Brain Cancer
November 21, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations
November 16, 2022
Via
Investor Brand Network
Researchers Turn to AI for Insights on Treating Brain Tumors
November 15, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update
November 15, 2022
Via
Investor Brand Network
Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence
November 14, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
November 14, 2022
Via
Investor Brand Network
Research Finds New Therapy Path for Brain Cancer
November 10, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM
November 10, 2022
Via
Investor Brand Network
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.